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Polymers, Encapsulation, and Artifical Organs
(Report on Session 26.0)
Washington D.C., July 15, 1992
Paul R. Sanberg, Thomas B. Freeman and David W. Cahill
Division

ofNeurological Surgery, Departments of Surgery, Psychiatry, Pharmacology and Therapeutics
University of South Florida College of Medicine
12901 Bruce B. Downs Blvd., MDC Box 16, Tampa, FL 33612-4799, USA

The session "Polymers, Encapsulation, and
Artificial Organs" at the Fourth International
Symposium on Neurotransplantation consisted of
five presentations examining the possibility that
polymer capsules with or without cells could have
therapeutic application for various neurological
diseases. Dr. Robert Langer of the Massachusetts
Institute of Technology provided an introduction to
the use of polymers as systems for controlled
release, long-term drug delivery/4/. Some of these
systems are currently in use for the treatment of
ophthalmic diseases, tobacco addiction, and birth
control, and can continuously release drugs for
over one year.
Of interest is the use of these slow releasing
polymers for delivering drugs and chemicals
directly into the brain, bypassing the blood-brain
barrier. Polyanhydride-containing bio-erodible
polymers were discussed as a way to introduce
both large and small molecules into the brain. Dr.
Langer suggested that polymers which release
drugs by surface erosion, thereby leading to nearly
constant release rates, may be the most appropriate
delivery system for CNS applications. The
polymers are now used clinically in over 56
medical centers in an FDA-approved study
examining delivery of BCNU in post-operative
patients with primary cerebral malignancy. These
polyanhydride polymer wafers are placed in the
resection cavity and provide a sustained release of
the chemotherapeutic agent. Dr. Langer reported
preliminary data demonstrating increased efficacy
of the localized BCNU polymer implants over
intravenous systemic administration/4/.
In another possible application it was shown
that polymers impregnated with dopamine could
release the compound steadily for over a year.
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Studies examining dopamine releasing polymers in
Parkinson’s disease models are currently underway
in several laboratories.
Dr. Patrick Aebischer from Brown University
presented an overview of data showing the use of
polymer membranes to encapsulate cells for
transplantation into the nervous system/1/. While
the previous presentation described polymers
impregnated with dopamine for transplantation into
parkinsonian brains, Dr. Aebischer described data
demonstrating that dopamine secreting cells can be

encapsulated by thermoplastic polymer membranes
and virtually made into a living dopamine minipump. These polymer membranes with maximum
molecular porosity at about 50,000 MW impair
host rejection via either antibody or cellular
responses. This allows the use of xenogeneic or
allogeneic transplants without the need for
The
pharmacological
immunosuppression.
subsequent presentation by Dr. Meg Palmatier from
CytoTherapeutics, Inc. gave further details of the
basic science and potential clinical application of
these encapsulated dopamine implants for
Parkinson’s disease/2/. The commercial utilization
of these implants involves the use of PC12 cells in
PAN/PVC membranes which will be implanted
directly into the striata of Parkinson’s disease
animal models and humans. These implants were
shown to release dopamine continuously and to
improve behavioral recovery in rodent and primate
models. This product was noted to be undergoing
safety and toxicology studies in preparation for
commercial marketing. Of interest were additional
data which demonstrated that implanting these
dopamine sources into aged rodents seemed to
improve some of the abnormal motor behavior seen
in aged animals.
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In regard to applications of this technology in
other models, Dr. Aebischer provided data showing
that encapsulated fibroblasts genetically engineered
to release NGF could improve an animal model of
Alzheimer’s disease based on medial septal
cholinergic lesions /1/. Finally, Dr. Aebischer
described the use of polymer capsules and tubes to
produce a regenerative environment for the nervous
system. By loading the polymers with cells and/or
impregnating them with bioactive molecules, such
as growth or trophic factors, he suggested that
these tubular conduits can induce or enhance
regeneration, and guide regenerating neural
elements to their appropriate targets. Similarly, in a
subsequent presentation by Dr. Larry Kromer of
Georgetown University /3/, data were presented
that compared the amount of regeneration of the
septal hippocampal cholinergic system within a
three dimensional organization of extracellular
matrix cables seeded with or without Schwann
cells. Using selectively permeable polymer
channels similar to those used by Dr. Aebischer’s
group, he demonstrated that specimens survived for
months and promoted regeneration of axons
through these cables from the septum to the
hippocampus. Their observations support the
hypothesis that Schwann cells produce a more
favorable environment than do endogenous CNS
glia for axonal regeneration, probably by producing
growth factors and cell adhesion molecules
necessary for such regeneration to occur.
The application of these polymer channel
technologies goes beyond the experiments on
cholinergic system regeneration presented by the
groups of Aebischer and Kromer. Clearly there is
future use for these channels in spinal cord injury
and other sensory/motor system regeneration. The
presentation by Dr. Woerly of the Czecholslovakian Academy of Sciences discussed the use
of another type of polymer matrix for neural
transplantation/5/. Hydrogels were shown to form
porous matrices, which, when coated with collagen,
could serve as artificial bridge substrates and
regeneration templates for CNS lesions. Cells
attached to the polymers could be maintained in
vitro, where they were shown to differentiate and
extend axons throughout the hydrogel’s surface.
Such hydrogels may have application in

transplantation of neural tissue in which axons are
required to extend into the host brain.
Immunoprotective thermoplastic membranes, as
discussed above, do not allow for anatomical
connections between the transplanted and host cells
because of their small pore size. Hydrogels may
serve as a potentially important matrix for
implantation of cells within the brain that need to
make functional connections. If these hydrogels are
impregnated with surface active molecules, such as
basement membrane proteins, glucosamine or
various peptides, they can provide substrates that
influence cell adhesion, differentiation and axonal
growth of the transplanted cells, thereby facilitating
restoration of function compared to transplantation
of the cells alone. This strategy may also facilitate
the survival of the transplanted cells prior to
transplantation since various growth promoting
substances can be used with the hydrogel matrix.
Interestingly, the scientists from CytoTherapeutics, Inc. /2/ and Dr. Aebischer’s lab /1/
discussed data combining hydrogel and other types
of matrices within the immunoprotective outer
thermoplastic polymer membranes used in these
encapsulated cell implants. The matrices were
shown to provide a substrate for enhanced growth
and survival of cells within the thermoplastic
membranes in both in vitro and in vivo animal
studies.

In summary, the session on "polymers,
encapsulation and artificial organs" provided
important data demonstrating the unique nature of
intracerebral application of polymers of different
types with and without cells and their potential
clinical application. In the periphery, some
prosthetic implants have been noted to produce
tissue scarring and poor biocompatibility over time.
Interestingly, polymer implants into the brain
seemed significantly biocompatible, with little
inflammatory scarring, edema or immune response.
Nevertheless, before polymer implants are used in
humans, additional long-term data will be needed
on their biocompatibility and sustained function.
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